| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Integrin beta-8, ITGB8 |
| Entrez GeneID | 3696 |
| WB Predicted band size | 85.6kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | This ITGB8 antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between 197-231 amino acids from the Central region of human ITGB8. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于ITGB8抗体的3篇代表性文献示例(注：文献为假设性描述，实际引用需核实)：
---
1. **文献名称**：*"Integrin β8 regulates dendritic cell-mediated T cell activation through TGF-β signaling modulation"*
**作者**：Smith A, et al.
**摘要**：该研究利用特异性ITGB8抗体阻断整合素β8与αv亚基的结合，发现其抑制树突状细胞中TGF-β的活化，从而降低T细胞免疫耐受，为自身免疫疾病治疗提供潜在靶点。
---
2. **文献名称**：*"Anti-ITGB8 antibody suppresses glioma progression by disrupting tumor vasculature"*
**作者**：Zhang Y, et al.
**摘要**：研究者开发了一种人源化ITGB8单克隆抗体，证明其可通过抑制内皮细胞中ITGB8/αv复合物的功能，破坏胶质瘤血管生成，显著延缓小鼠模型中的肿瘤生长。
---
3. **文献名称**：*"Structural characterization of a neutralizing antibody targeting integrin β8 for fibrosis therapy"*
**作者**：Wang H, et al.
**摘要**：本文解析了ITGB8抗体与抗原表位的晶体结构，揭示其中和ITGB8介导的TGF-β激活的分子机制，并在肺纤维化模型中验证了抗体的治疗潜力。
---
**注意**：以上文献为示例性质，实际研究中请通过PubMed或Web of Science等数据库检索真实文献。关键词建议：**"integrin beta8 antibody"**, **"anti-ITGB8 therapeutic"**, **"ITGB8 TGF-beta"**。
The integrin β8 (ITGB8) antibody targets the β8 subunit of the αvβ8 integrin heterodimer, a cell-surface receptor involved in mediating cell-extracellular matrix (ECM) interactions and modulating signaling pathways. Integrins are transmembrane proteins critical for cell adhesion, migration, and signal transduction. The αvβ8 integrin specifically binds to latent transforming growth factor-beta (TGF-β) complexes via its Arg-Gly-Asp (RGD) motif, playing a unique role in activating TGF-β, a key regulator of immune homeostasis, fibrosis, and tumor progression. This activation mechanism is essential for processes like vascular development, neurobiology, and immune cell regulation.
ITGB8 is prominently expressed in endothelial cells, glial cells, and certain epithelial or tumor cells. Research highlights its dual role in both physiological and pathological contexts. In the immune system, αvβ8-mediated TGF-β activation regulates T-cell differentiation and suppresses excessive inflammation, while in cancer, it can promote immunosuppression, angiogenesis, and metastasis. Dysregulation of ITGB8 has been linked to diseases such as idiopathic pulmonary fibrosis, glioblastoma, and inflammatory bowel disease.
Antibodies against ITGB8 are valuable tools for studying its function and therapeutic potential. Neutralizing ITGB8 antibodies have shown promise in preclinical models for blocking TGF-β activation, thereby mitigating fibrosis or enhancing antitumor immunity. Additionally, these antibodies are used in diagnostic assays to assess ITGB8 expression levels in tissues, aiding in disease stratification and mechanistic studies. Ongoing research aims to refine ITGB8-targeted therapies to balance efficacy with minimal off-target effects.
×
